Pfizer’s lorlatinib clears first hurdle to UK early access scheme

21st August 2018 Uncategorised 0

Pfizer’s lorlatinib has been designated a Promising Innovative Medicine for the treatment of some patients with ALK-positive advanced non-small cell lung cancer.

More: Pfizer’s lorlatinib clears first hurdle to UK early access scheme
Source: News